Dialysis: The sweetness of glitazones: Randomized trials needed

Nature Reviews Nephrology

Volumn 5, Issue 9, 2009, Pages 497-498

  Zoccali, Carmine ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIALYSIS; DRUG MECHANISM; HEART INFARCTION; HUMAN; KIDNEY FAILURE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; SYSTEMATIC REVIEW;

COMBINED MODALITY THERAPY; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; THIAZOLIDINEDIONES;

EID: 70349325859     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.127     Document Type: Short Survey

References (10)

1. Brunelli S. M., Thadhani R. ikizler T. A. & Feldman H. i. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int. 75, 961-968 (2009).
2. Ramirez, S. P. B. et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J. Am. Soc. Nephrol. 20, 1094-1101 (2009).
3. Nissen, S. E. & wolski, K. effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007). (Pubitemid 46919772)
4. Lincoff, A. M., wolski, K., nicholls, S. J. & nissen, S. E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298, 1180-1188 (2007).
5. Schneider, C. A. et al. effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J. Am. Soc. Nephrol. 19, 182-187 (2008).
6. Joffe, M. M. & Rosenbaum, P. R. invited commentary: propensity scores. Am. J. Epidemiol. 150, 327-333 (1999).
7. Mason, N. A. et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am. J. Kidney Dis. 45, 119-126 (2005).
8. Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005). (Pubitemid 41058323)
9. Fellström, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
10. Korevaar, J. C. et al. effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: A randomized controlled trial. Kidney Int. 64, 2222-2228 (2003).